Publications

Optimising health benefit packages in the era of COVID-19: A case study from Pakistan (Accepted).

TORRES RUEDA, S; Kitson, N; BOZZANI, F; SWEENEY, S; Raza, W; Murad Shah, M; NAYLOR, N; PEARSON, C; EGGO, R; Quaife, M; PROCTER, S; Huda, M; CHiL COVID Working Group,; Jit, M; VASSALL, A;

2022

(2022).

Overall and cause-specific hospitalisation and death after COVID-19 hospitalisation in England: A cohort study using linked primary care, secondary care, and death registration data in the OpenSAFELY platform.

BHASKARAN, K; RENTSCH, CT; Hickman, G; Hulme, WJ; SCHULTZE, A; Curtis, HJ; WING, K; WARREN-GASH, C; TOMLINSON, L; Bates, CJ; MATHUR, R; MacKenna, B; MAHALINGASIVAM, V; WONG, A; Walker, AJ; Morton, CE; GRINT, D; Mehrkar, A; EGGO, RM; Inglesby, P; DOUGLAS, IJ; MCDONALD, HI; Cockburn, J; WILLIAMSON, EJ; Evans, D; ... GOLDACRE, B.

2022

PLoS medicine, (2022).19 1 10.1371/journal.pmed.1003871.

The cost and cost-effectiveness of novel tuberculosis vaccines in low- and middle-income countries: a modelling study.

Portnoy, A; Clark, R; Quaife, M; WEERASURIYA, C; Mukandavire, C; Bakker, R; Deol, A; Malhotra, S; Gebreselassie, N; Zignol, M; Sim, SY; Hutubessy, RC W; Baena, IG; Nishikiori, N; JIT, M; WHITE, R; Menzies, N;

2022

medRxiv (2022). 10.1101/2022.05.04.22274654.

Estimating the cost-effectiveness of maternal vaccination and monoclonal antibodies for respiratory syncytial virus in Kenya and South Africa.

KOLTAI, M; Moyes, J; Nyawanda, B; Nyiro, J; Munywoki, P; Tempia, S; Li, X; Antillon, M; Bilcke, J; Flasche, S; Beutels, P; Nokes, J; Cohen, C; JIT, M;

2022

medRxiv (2022). 10.1101/2022.09.09.22279780.

Unmasking Pneumococcal Carriage in a High Human Immunodeficiency Virus (HIV) Prevalence Population in two Community Cohorts in South Africa, 2016-2018: The PHIRST Study.

Carrim, M; Tempia, S; THINDWA, D; Martinson, NA; Kahn, K; FLASCHE, S; Hellferscee, O; Treurnicht, FK; McMorrow, ML; Moyes, J; Mkhencele, T; Mathunjwa, A; Kleynhans, J; Lebina, L; Mothlaoleng, K; Wafawanaka, F; Gómez-Olivé, FX; Cohen, C; Von Gottberg, A; Wolter, N; PHIRST group,;

2022

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, (2022).76 3 10.1093/cid/ciac499.

RESIST2: Policy.

Knight, G;

2022

, London School of Hygiene & Tropical Medicine (2022). 10.17037/PUBS.04669769.

Evaluating and mitigating the potential indirect effect of COVID-19 on control programmes for seven neglected tropical diseases: a modelling study.

Borlase, A; Le Rutte, EA; Castaño, S; Blok, DJ; Toor, J; Giardina, F; Davis, EL; NTD Modelling Consortium,;

2022

The Lancet Global health, (2022).10 11 10.1016/S2214-109X(22)00360-6.

Recent economic evaluation of 1-dose HPV vaccination uses unsupported assumptions.

Burger, E; Baussano, I; Kim, JJ; Laprise, J-F; Berkhof, J; Schiller, JT; Canfell, K; PREM, K; Brisson, M; JIT, M; Barnabas, RV;

2022

Vaccine, (2022).41 16 10.1016/j.vaccine.2022.07.022.

Group B streptococcus infection during pregnancy and infancy: estimates of regional and global burden.

Gonçalves, BP; PROCTER, SR; PAUL, P; CHANDNA, J; LEWIN, A; Seedat, F; Koukounari, A; Dangor, Z; Leahy, S; Santhanam, S; John, HB; Bramugy, J; Bardají, A; Abubakar, A; Nasambu, C; Libster, R; Sánchez Yanotti, C; Horváth-Puhó, E; Sørensen, HT; Van de Beek, D; Bijlsma, MW; Gardner, WM; Kassebaum, N; Trotter, C; Bassat, Q; ... CHAMPS team,

2022

The Lancet. Global health, (2022).10 6 10.1016/S2214-109X(22)00093-6.

A cluster-randomised, non-inferiority trial of the impact of a two-dose compared to three-dose schedule of pneumococcal conjugate vaccination in rural Gambia: the PVS trial.

MACKENZIE, GA; OSEI, I; Salaudeen, R; Hossain, I; Young, B; Secka, O; D'ALESSANDRO, U; Palmu, AA; Jokinen, J; Hinds, J; FLASCHE, S; Mulholland, K; Nguyen, C; GREENWOOD, B;

2022

Trials, (2022).23 1 10.1186/s13063-021-05964-5.